$22.55
Live
Insights on Bicycle Therapeutics Plc
Revenue is down for the last 3 quarters, 11.39M → 5.33M (in $), with an average decrease of 26.7% per quarter
Netprofit is up for the last 2 quarters, -49.89M → -49.09M (in $), with an average increase of 1.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 38.6%
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 274.2%
0.43%
Downside
Day's Volatility :3.74%
Upside
3.32%
44.39%
Downside
52 Weeks Volatility :56.62%
Upside
22.0%
Period | Bicycle Therapeutics Plc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 29.6% | 1.9% | 0.0% |
6 Months | 42.64% | 10.7% | 0.0% |
1 Year | 12.33% | 4.6% | -1.1% |
3 Years | -27.54% | 14.2% | -22.1% |
Market Capitalization | 856.9M |
Book Value | $8.74 |
Earnings Per Share (EPS) | -5.08 |
Wall Street Target Price | 43.2 |
Profit Margin | 0.0% |
Operating Margin TTM | -1017.35% |
Return On Assets TTM | -23.6% |
Return On Equity TTM | -56.31% |
Revenue TTM | 27.0M |
Revenue Per Share TTM | 0.76 |
Quarterly Revenue Growth YOY | 67.4% |
Gross Profit TTM | -67.1M |
EBITDA | -183.4M |
Diluted Eps TTM | -5.08 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.19 |
EPS Estimate Next Year | -5.52 |
EPS Estimate Current Quarter | -1.23 |
EPS Estimate Next Quarter | -1.24 |
What analysts predicted
Upside of 91.57%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.1M | ↑ 246.41% |
Net Income | -21.8M | ↑ 34.36% |
Net Profit Margin | -306.14% | ↑ 483.13% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 13.8M | ↑ 93.4% |
Net Income | -30.6M | ↑ 40.11% |
Net Profit Margin | -221.78% | ↑ 84.36% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 10.4M | ↓ 24.72% |
Net Income | -51.0M | ↑ 66.66% |
Net Profit Margin | -490.95% | ↓ 269.17% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 11.7M | ↑ 12.58% |
Net Income | -66.8M | ↑ 30.99% |
Net Profit Margin | -571.25% | ↓ 80.3% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 14.5M | ↑ 23.65% |
Net Income | -112.7M | ↑ 68.69% |
Net Profit Margin | -779.35% | ↓ 208.1% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 27.0M | ↑ 86.52% |
Net Income | -180.7M | ↑ 60.28% |
Net Profit Margin | -669.72% | ↑ 109.63% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.0M | ↓ 30.56% |
Net Income | -28.3M | ↑ 5.66% |
Net Profit Margin | -932.47% | ↓ 319.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.2M | ↑ 4.77% |
Net Income | -30.0M | ↑ 5.75% |
Net Profit Margin | -941.22% | ↓ 8.75% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.9M | ↑ 53.72% |
Net Income | -39.1M | ↑ 30.31% |
Net Profit Margin | -797.88% | ↑ 143.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.4M | ↑ 132.78% |
Net Income | -42.6M | ↑ 9.06% |
Net Profit Margin | -373.81% | ↑ 424.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.4M | ↓ 53.04% |
Net Income | -49.9M | ↑ 17.12% |
Net Profit Margin | -932.32% | ↓ 558.51% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.3M | ↓ 0.39% |
Net Income | -49.1M | ↓ 1.6% |
Net Profit Margin | -921.01% | ↑ 11.31% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 81.6M | ↑ 10.3% |
Total Liabilities | 151.5M | ↑ 24.98% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 110.2M | ↑ 35.0% |
Total Liabilities | 17.0M | ↓ 88.78% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 161.2M | ↑ 46.24% |
Total Liabilities | 65.7M | ↑ 286.51% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 479.8M | ↑ 197.73% |
Total Liabilities | 133.5M | ↑ 103.28% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 410.6M | ↓ 14.42% |
Total Liabilities | 139.8M | ↑ 4.71% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 595.3M | ↑ 44.99% |
Total Liabilities | 224.4M | ↑ 60.49% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 417.1M | ↓ 6.36% |
Total Liabilities | 127.7M | ↓ 4.78% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 410.6M | ↓ 1.57% |
Total Liabilities | 139.8M | ↑ 9.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 428.8M | ↑ 4.43% |
Total Liabilities | 185.6M | ↑ 32.76% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 454.2M | ↑ 5.92% |
Total Liabilities | 234.1M | ↑ 26.09% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 638.7M | ↑ 40.63% |
Total Liabilities | 222.7M | ↓ 4.88% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 595.3M | ↓ 6.79% |
Total Liabilities | 224.4M | ↑ 0.79% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.1M | ↑ 1742.97% |
Investing Cash Flow | -1.2M | ↑ 6.56% |
Financing Cash Flow | 25.4M | ↓ 56.06% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.6M | ↑ 9.72% |
Investing Cash Flow | -1.6M | ↑ 31.11% |
Financing Cash Flow | 58.4M | ↑ 129.81% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.8M | ↓ 37.83% |
Investing Cash Flow | -1.2M | ↓ 22.83% |
Financing Cash Flow | 62.8M | ↑ 7.53% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.8M | ↓ 16.84% |
Investing Cash Flow | -2.0M | ↑ 69.17% |
Financing Cash Flow | 320.7M | ↑ 410.36% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -86.1M | ↑ 482.07% |
Investing Cash Flow | -19.0M | ↑ 835.32% |
Financing Cash Flow | 6.7M | ↓ 97.91% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.9M | ↓ 75.05% |
Investing Cash Flow | -3.0M | ↓ 69.55% |
Financing Cash Flow | 159.0K | ↓ 18.46% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.3M | ↑ 416.25% |
Investing Cash Flow | -1.4M | ↓ 51.47% |
Financing Cash Flow | 5.9M | ↑ 3603.14% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -46.4M | ↑ 53.13% |
Investing Cash Flow | -277.0K | ↓ 80.87% |
Financing Cash Flow | 2.7M | ↓ 53.84% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 34.1M | ↓ 173.47% |
Investing Cash Flow | -277.0K | ↑ 0.0% |
Financing Cash Flow | 12.3M | ↑ 352.24% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.0M | ↓ 103.01% |
Investing Cash Flow | -502.0K | ↑ 81.23% |
Financing Cash Flow | 234.6M | ↑ 1808.81% |
Sell
Neutral
Buy
Bicycle Therapeutics Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Bicycle Therapeutics Plc | -10.81% | 42.64% | 12.33% | -27.54% | 89.0% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Bicycle Therapeutics Plc | NA | NA | NA | -5.19 | -0.56 | -0.24 | NA | 8.74 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Bicycle Therapeutics Plc | Buy | $856.9M | 89.0% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Paradigm Biocapital Advisors LP
Deep Track Capital, LP
Jefferies Financial Group Inc
Baker Bros Advisors LP
Tybourne Capital Management (HK) Ltd
First Light Asset Management, LLC
Bicycle Therapeutics Plc’s price-to-earnings ratio stands at None
Read Morebicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun
Organization | Bicycle Therapeutics Plc |
Employees | 284 |
CEO | Dr. Kevin Lee M.B.A., Ph.D. |
Industry | Biotechnology |